Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kazuo Noguchi

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
The Journal of Dermatology|April 18, 2012
Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphomaHidefumi Wada, Ryoji Tsuboi, Yukihiko Kato, et al.
Respiratory Investigation|March 4, 2025
A phase 1 study of pembrolizumab plus ipilimumab as first-line treatment in Japanese patients with advanced non-small-cell lung cancerNaoyuki Nogami, Shigeki Umemura, Toshiyuki Kozuki, et al.
Cancer Treatment and Research Communications|October 4, 2021
Phase 1 study of pembrolizumab plus chemotherapy as first-line treatment in Japanese patients with advanced NSCLCTakayasu Kurata, Kazuhiko Nakagawa, Miyako Satouchi, et al.
International Journal of Clinical Oncology|January 12, 2012
Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trialToshihiko Doi, Tetsuya Hamaguchi, Kuniaki Shirao, et al.
Biological & Pharmaceutical Bulletin|December 8, 2024
Chronotropic and Inotropic Effects of Sudachitin, a Polymethoxyflavone from the Peel of Citrus sudachi on Isolated Rat Atria and Its Underlying MechanismsKazuo Noguchi, Saki Umeda, Misaki Goma, et al.
Pharmacology|December 4, 2001
Effects of HNS-32, a novel antiarrhythmic agent, on guinea-pig myocardiumKazuo Noguchi, Junya Kase, Mariko Saitoh, et al.
Biological & Pharmaceutical Bulletin|January 7, 2026
Possible Involvement of β<sub>1</sub>-Adrenoceptors in the Positive Chronotropic Effects of MirabegronKazuo Noguchi, Aino Nagai, Nana Kashimoto, et al.
Investigational New Drugs|February 1, 2024
Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancerNaoyuki Nogami, Takaaki Tokito, Yoshitaka Zenke, et al.
Cancer Chemotherapy and Pharmacology|August 8, 2013
Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancerToshihiko Doi, Kei Muro, Takayuki Yoshino, et al.
Cancer Chemotherapy and Pharmacology|June 25, 2015
Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumorsToshihiko Doi, Kenji Tamura, Yuko Tanabe, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
The Journal of Dermatology|April 18, 2012
Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphomaHidefumi Wada, Ryoji Tsuboi, Yukihiko Kato, et al.
Respiratory Investigation|March 4, 2025
A phase 1 study of pembrolizumab plus ipilimumab as first-line treatment in Japanese patients with advanced non-small-cell lung cancerNaoyuki Nogami, Shigeki Umemura, Toshiyuki Kozuki, et al.
Cancer Treatment and Research Communications|October 4, 2021
Phase 1 study of pembrolizumab plus chemotherapy as first-line treatment in Japanese patients with advanced NSCLCTakayasu Kurata, Kazuhiko Nakagawa, Miyako Satouchi, et al.
International Journal of Clinical Oncology|January 12, 2012
Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trialToshihiko Doi, Tetsuya Hamaguchi, Kuniaki Shirao, et al.
Biological & Pharmaceutical Bulletin|December 8, 2024
Chronotropic and Inotropic Effects of Sudachitin, a Polymethoxyflavone from the Peel of Citrus sudachi on Isolated Rat Atria and Its Underlying MechanismsKazuo Noguchi, Saki Umeda, Misaki Goma, et al.
Pharmacology|December 4, 2001
Effects of HNS-32, a novel antiarrhythmic agent, on guinea-pig myocardiumKazuo Noguchi, Junya Kase, Mariko Saitoh, et al.
Biological & Pharmaceutical Bulletin|January 7, 2026
Possible Involvement of β<sub>1</sub>-Adrenoceptors in the Positive Chronotropic Effects of MirabegronKazuo Noguchi, Aino Nagai, Nana Kashimoto, et al.
Investigational New Drugs|February 1, 2024
Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancerNaoyuki Nogami, Takaaki Tokito, Yoshitaka Zenke, et al.
Cancer Chemotherapy and Pharmacology|August 8, 2013
Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancerToshihiko Doi, Kei Muro, Takayuki Yoshino, et al.
Cancer Chemotherapy and Pharmacology|June 25, 2015
Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumorsToshihiko Doi, Kenji Tamura, Yuko Tanabe, et al.
Pageof 4